ArticleMikrochimica acta2025
In situ formation of fluorescent non-conjugated polymer dots for α-glucosidase activity assay and inhibitor screening.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A novel and facile fluorescence turn-on assay for detecting α-glucosidase (α-Glu) activity and screening inhibitors is reported. This assay exploits α-Glu-catalyzed hydrolysis of L-ascorbic acid-2-O-α-D-glucopyranosyl (AA2G) to release ascorbic acid (AA), triggering an in situ fluorogenic reaction with N-methylethylenediamine (N-MEDA) that generates non-conjugated polymer dots (NCPDs). These NCPDs emit blue fluorescence at 425 nm upon excitation at 350 nm, and the fluorescence intensity increases proportionally with the concentration of α-Glu, enabling quantitative detection of enzymatic activity. The fluorescent assay demonstrates a linear response ranging from 0.01 to 10 U/mL and achieves a low detection limit of 0.0034 U/mL, surpassing most existing methods in sensitivity and width of linear range. In addition, the proposed method has been successfully applied to screen α-Glu inhibitors (AGIs) and determine α-Glu activity in real samples, yielding satisfying results. This work introduces a robust analytical framework and promising approach for clinical diagnosis and anti-diabetic drug discovery.
Indexed as
Identifiers
40779177What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.